|
| Press Releases |
|
 |
|
| Tuesday, October 3, 2023 |
|
|
HanchorBio Announces First Patient Dosed in the Phase 1 Multi-Regional Clinical Trial of HCB101 |
| more info >> |
|
| Monday, August 28, 2023 |
|
|
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies |
| HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies more info >> |
|
|
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies |
| HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies more info >> |
|
| Monday, July 24, 2023 |
|
|
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
| HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma. more info >> |
|
|
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
| HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma. more info >> |
|
| Monday, April 17, 2023 |
|
|
HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
| more info >> |
|
|
HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
| HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Sri Lanka and the Middle East's top real estate achievements recognised at 2025 PropertyGuru Asia Property Awards
Dec 22, 2025 16:57: JST
|
|
|
MiniMax通過港交所聆訊 衝刺「AGI全球第一股」
Dec 22, 2025 15:59 HKT/SGT
|
|
|
MiniMax通过港交所聆讯 冲刺「AGI全球第一股」
Dec 22, 2025 15:46 HKT/SGT
|
|
|
三菱重工グループ、デジタル人材育成を加速
Dec 22, 2025 12:00: JST
|
|
|
聯想之星收穫第10個IPO
Dec 22, 2025 11:41 HKT/SGT
|
|
|
国内初、三菱重工とエクシオグループが二相式DLC方式のGPUサーバー構築・商用利用開始
Dec 22, 2025 11:40: JST
|
|
|
联想之星收获第10个IPO
Dec 22, 2025 11:30 HKT/SGT
|
|
|
印象大紅袍宣佈全球發售定價 每股發售股份發售價3.6港元 集資港幣1.3億元
Dec 22, 2025 10:00 HKT/SGT
|
|
|
印象大红袍宣布全球发售定价 每股发售股份发售价3.6港元 集资港币1.3亿元
Dec 22, 2025 10:00 HKT/SGT
|
|
|
Sri Lanka and the Middle East's top real estate achievements recognised at 2025 PropertyGuru Asia Property Awards
Dec 22, 2025 10:00 JST
|
|
|
西藏智汇矿业登陆港股：从高原走向国际 独特资源禀赋释放长期增长潜力
Dec 19, 2025 16:15 HKT/SGT
|
|
|
西藏智匯礦業登陸港股：從高原走向國際 獨特資源稟賦釋放長期增長潛力
Dec 19, 2025 15:35 HKT/SGT
|
|
|
A New Benchmark for Specialized Technology Stocks in Hong Kong! CiDi's Listing Marks a New Chapter in Commercial Intelligent Driving
Dec 19, 2025 10:30 HKT/SGT
|
|
|
トヨタ、米国生産トヨタ車の26年からの日本導入を検討
Dec 19, 2025 10:00: JST
|
|
|
Air T, Inc. Announces Closing of Regional Express Acquisition
Dec 19, 2025 06:10 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
